We are live on ! Find out more
BIOL icon

Biolase

Delisted

BIOL was delisted on the 18th of June, 2024.

28 hedge funds and large institutions have $17.8M invested in Biolase in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

7% more capital inflows, than outflows

Capital inflows: $2.7M | Capital outflows: $2.53M

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.93% less ownership

Funds ownership: 41.77% → 38.84% (-2.9%)

13% less funds holding

Funds holding: 32 → 28 (-4)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Holders
28
Holders Change
-4
Holders Change %
-12.5%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
5
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BIOL Hedge Fund Activity: Q3 2017 in Review

28 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Biolase (BIOL) for Q3 2017, worth a combined $17.8M — down 35% from $27.5M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BIOL and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was Oracle Investment Management, adding an estimated $2.55M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $1.12M sold.

  • 28 institutional investors held Biolase (BIOL) as of Q3 2017, down from 32 in Q2 2017.
  • Funds reported $17.8M of Biolase stock for Q3 2017, down 35% quarter-over-quarter.
  • 3 funds opened new Biolase positions in Q3 2017 and 6 closed out, a net change of -3 holders.
  • The largest Biolase buyer in Q3 2017 was Oracle Investment Management, an estimated $2.55M added.
  • The largest Biolase seller in Q3 2017 was Consonance Capital Management, an estimated $1.12M sold.

Based on aggregated 13F filings for Q3 2017.